

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

grant a product specific waiver

MHRA-100131-PIP01-21

### **Scope of the Application**

#### **Active Substance(s)**

ATEZOLIZUMAB

#### **Condition(s)**

Treatment of all malignant neoplasms (except CNS tumours, haematopoietic, lymphoid neoplasms)

#### **Pharmaceutical Form(s)**

Solution for injection

#### **Route(s) of Administration**

Subcutaneous use

#### **Name / Corporate name of the PIP applicant**

Roche Product Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Roche Product Limited submitted to the licensing authority on 28/05/2021 10:17 BST an application for a Waiver

The procedure started on 29/10/2021 14:49 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100131-PIP01-21

Of 10/11/2021 11:18 GMT

On the adopted decision for ATEZOLIZUMAB (MHRA-100131-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for ATEZOLIZUMAB, Solution for injection , Subcutaneous use .

This decision is addressed to Roche Product Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, United Kingdom, AL7 1TW

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms). The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Solution for injection Route(s) of administration: Subcutaneous use Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Not Applicable

#### 2.2 Indication(s) targeted by the PIP:

Not Applicable

**2.3 Subset(s) of the paediatric population concerned by the paediatric development:**

Not Applicable
----------------

**2.4 Pharmaceutical Form(s):**

Not Applicable
----------------

**2.5 Studies:**

<b>Study Type</b>	<b>Number of Studies</b>	<b>Study Description</b>
<b>Quality Measures</b>		
<b>Non-Clinical Studies</b>		
<b>Clinical Studies</b>		
<b>Extrapolation, Modeling &amp; Simulation Studies</b>		
<b>Other Studies</b>		
<b>Other Measures</b>		

**3. Follow-up, completion and deferral of a PIP:**

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	
<b>Date of completion of the paediatric investigation plan:</b>	
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	